Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 268,623,936
  • Shares Outstanding, K 6,830,000
  • Annual Sales, $ 67,325 M
  • Annual Income, $ 12,808 M
  • 60-Month Beta 0.44
  • Price/Sales N/A
  • Price/Cash Flow 12.59
  • Price/Book 7.91
Trade RHHBY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/01/24
  • Annual Dividend & Yield 0.85 (2.15%)
  • Most Recent Dividend 0.847 on 03/14/24
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 1.46
  • Number of Estimates 1
  • High Estimate 1.46
  • Low Estimate 1.46
  • Prior Year N/A
  • Growth Rate Est. (year over year) -99.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.0500 +7.65%
on 09/11/24
42.4300 -6.00%
on 08/30/24
-0.6750 (-1.66%)
since 08/16/24
3-Month
33.7600 +18.14%
on 07/08/24
42.4300 -6.00%
on 08/30/24
+4.9050 (+14.02%)
since 06/18/24
52-Week
29.2000 +36.59%
on 05/02/24
42.4300 -6.00%
on 08/30/24
+4.0250 (+11.22%)
since 09/18/23

Most Recent Stories

More News
Tap the Weight-Loss Drug Market With These ETFs

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...

RHHBY : 39.8850 (+1.41%)
NVO : 132.47 (+0.36%)
LLY : 907.01 (+0.09%)
HRTS : 34.87 (+0.71%)
THNR : 27.51 (+0.40%)
OZEM : 28.40 (+0.28%)
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)

Telemedicine once seemed like it was going to revolutionize healthcare.

LLY : 907.01 (+0.09%)
PFE : 29.79 (-0.13%)
NVO : 132.47 (+0.36%)
TDOC : 9.16 (+0.55%)
AMZN : 186.48 (-0.21%)
NVDA : 113.95 (-1.42%)
SFIX : 4.18 (+1.95%)
VKTX : 64.74 (+2.86%)
ALT : 7.45 (-1.59%)
RHHBY : 39.8850 (+1.41%)
HIMS : 16.39 (+1.80%)
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a broader population.The...

REGN : 1,142.29 (-0.39%)
SNY : 57.24 (+0.58%)
RHHBY : 39.8850 (+1.41%)
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab).The SC formulation was approved under the brand name Tecentriq...

NVS : 116.00 (+0.26%)
RHHBY : 39.8850 (+1.41%)
LLY : 907.01 (+0.09%)
Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe

Roche RHHBY is set to enter the competitive continuous glucose monitor (CGM) market in Europe following the CE mark approval of its Accu-Chek Smartguide in July.The Swiss pharmaceutical company plans to...

ABT : 115.39 (-2.32%)
RHHBY : 39.8850 (+1.41%)
ISRG : 481.56 (-0.36%)
DXCM : 69.62 (+0.99%)
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track.

MS : 99.69 (-0.15%)
LLY : 907.01 (+0.09%)
VKTX : 64.74 (+2.86%)
RHHBY : 39.8850 (+1.41%)
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The FDA has granted approval to 29 novel drugs this year. Innovation in the industry...

NVS : 116.00 (+0.26%)
RHHBY : 39.8850 (+1.41%)
PFE : 29.79 (-0.13%)
LLY : 907.01 (+0.09%)
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug

Roche RHHBY presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting.CT-996 is an investigational, once-daily,...

RHHBY : 39.8850 (+1.41%)
NVO : 132.47 (+0.36%)
LLY : 907.01 (+0.09%)
Why Roche Holdings Stock Withered on Wednesday

The company had a dispiriting update to offer about an investigational drug.

NVO : 132.47 (+0.36%)
LLY : 907.01 (+0.09%)
RHHBY : 39.8850 (+1.41%)
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous urticaria (CSU)...

REGN : 1,142.29 (-0.39%)
SNY : 57.24 (+0.58%)
NVS : 116.00 (+0.26%)
RHHBY : 39.8850 (+1.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 39.7433
2nd Resistance Point 39.5967
1st Resistance Point 39.4633
Last Price 39.8850
1st Support Level 39.1833
2nd Support Level 39.0367
3rd Support Level 38.9033

See More

52-Week High 42.4300
Last Price 39.8850
Fibonacci 61.8% 37.3761
Fibonacci 50% 35.8150
Fibonacci 38.2% 34.2539
52-Week Low 29.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar